Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2023-2030
The Biosimulation Market is projected to reach USD 9.87 billion by 2030 from USD 3.29 billion in 2022, at a CAGR of 14.71% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Biosimulation Market.
- Based on Offering, market is studied across Services and Software. The Services is further studied across Contract Services and In-House Services. The Software is further studied across Molecular Modeling & Simulation Software, PBPK Modeling & Simulation Software, PK/PD Modeling & Simulation Software, Toxicity Prediction Software, and Trial Design Software. The Software commanded largest market share of 77.65% in 2022, followed by Services.
- Based on Delivery Model, market is studied across Ownership Models and Subscription Models. The Ownership Models commanded largest market share of 60.46% in 2022, followed by Subscription Models.
- Based on End-User, market is studied across Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Regulatory Authorities, and Research Institutes. The Pharmaceutical & Biotechnology Companies commanded largest market share of 47.54% in 2022, followed by Contract Research Organizations.
- Based on Application, market is studied across Drug Development and Drug Discovery. The Drug Development is further studied across Clinical Trials and Preclinical Testing. The Preclinical Testing is further studied across ADME/Tox and PK/PD. The Drug Discovery is further studied across Lead Identification & Optimization and Target Identification & Validation. The Drug Development commanded largest market share of 53.33% in 2022, followed by Drug Discovery.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 42.52% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Biosimulation Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Biosimulation Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systèmes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Biosimulation Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Biosimulation Market?
- What is the competitive strategic window for identifying opportunities in the Biosimulation Market?
- What are the latest technology trends and regulatory frameworks in the Biosimulation Market?
- What is the market share of the leading vendors in the Biosimulation Market?
- Which modes and strategic moves are suitable for entering the Biosimulation Market?
Please Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Biosimulation Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing emphasis on research of personalized medicine
- 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
- 5.1.2. Restraints
- 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
- 5.1.3.2. Rising investments for drug developments and drug testings
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
- 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
- 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Biosimulation Market, by Offering
- 6.1. Introduction
- 6.2. Services
- 6.3.1. Contract Services
- 6.3.2. In-House Services
- 6.3. Software
- 6.4.1. Molecular Modeling & Simulation Software
- 6.4.2. PBPK Modeling & Simulation Software
- 6.4.3. PK/PD Modeling & Simulation Software
- 6.4.4. Toxicity Prediction Software
- 6.4.5. Trial Design Software
- 7. Biosimulation Market, by Delivery Model
- 7.1. Introduction
- 7.2. Ownership Models
- 7.3. Subscription Models
- 8. Biosimulation Market, by End-User
- 8.1. Introduction
- 8.2. Contract Research Organizations
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.4. Regulatory Authorities
- 8.5. Research Institutes
- 9. Biosimulation Market, by Application
- 9.1. Introduction
- 9.2. Drug Development
- 9.3.1. Clinical Trials
- 9.3.2. Preclinical Testing
- 9.3.3.1. ADME/Tox
- 9.3.3.2. PK/PD
- 9.3. Drug Discovery
- 9.4.1. Lead Identification & Optimization
- 9.4.2. Target Identification & Validation
- 10. Americas Biosimulation Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
- 11. Asia-Pacific Biosimulation Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
- 12. Europe, Middle East & Africa Biosimulation Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
- 13. Competitive Landscape
- 13.1. FPNV Positioning Matrix
- 13.2. Market Share Analysis, By Key Player
- 13.3. Competitive Scenario Analysis, By Key Player
- 13.3.1. Merger & Acquisition
- 13.3.1.1. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
- 13.3.1.2. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
- 13.3.1.3. Resolution Medical Acquires LifeTec Group
- 13.3.2. Agreement, Collaboration, & Partnership
- 13.3.2.1. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
- 13.3.2.2. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
- 13.3.2.3. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
- 13.3.2.4. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
- 13.3.3. New Product Launch & Enhancement
- 13.3.3.1. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
- 13.3.3.2. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
- 13.3.3.3. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
- 13.3.3.4. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
- 13.3.4. Investment & Funding
- 13.3.4.1. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life
- 13.3.5. Award, Recognition, & Expansion
- 13.3.5.1. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
- 13.3.5.2. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
- 14. Competitive Portfolio
- 14.1. Key Company Profiles
- 14.1.1. Advanced Chemistry Development, Inc.
- 14.1.2. Aitia
- 14.1.3. Allucent
- 14.1.4. Applied BioMath, LLC
- 14.1.5. Biomed Simulation, Inc.
- 14.1.6. BioSimulation Consulting Inc.
- 14.1.7. Cadence Design Systems, Inc.
- 14.1.8. Cell Works Group, Inc.
- 14.1.9. Certara, Inc.
- 14.1.10. Chemical Computing Group ULC
- 14.1.11. Compugen Ltd.
- 14.1.12. Crystal Pharmatech Co., Ltd.
- 14.1.13. Dassault Systèmes SE
- 14.1.14. Genedata AG
- 14.1.15. Immunetrics Inc
- 14.1.16. In Silico Biosciences, Inc.
- 14.1.17. INOSIM Software GmbH
- 14.1.18. Instem PLC
- 14.1.19. Laboratory Corporation of America Holdings
- 14.1.20. Model Vitals
- 14.1.21. Physiomics PLC
- 14.1.22. Quotient Sciences Limited
- 14.1.23. Resolution Medical
- 14.1.24. Rosa & Co LLC
- 14.1.25. Schrodinger, Inc.
- 14.1.26. Simulations Plus, Inc.
- 14.1.27. Thermo Fisher Scientific Inc.
- 14.1.28. VeriSIM Life.
- 14.1.29. VIRTUALMAN
- 14.1.30. Yokogawa Electric Corporation
- 14.2. Key Product Portfolio
- 15. Appendix
- 15.1. Discussion Guide
- 15.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook